Praxis reports FY2022 net loss $214M; cash $100.5M, runway into 1Q24

Praxis Precision Medicines, Inc.

2022-FY EPS reported -$4.64

Cash and investments $100.5M as of Dec 31, 2022, down from $275.9M; expected to fund ops into 1Q24.
Net loss FY2022 $214.0M vs $167.1M; Q4 net loss $41.2M.
R&D expense FY2022 $155.0M, up from $120.3M, reflecting Cerebrum/Solidus platform spending.
Phase 2b ulixacaltamide topline results for essential tremor expected in 1Q23.
Entered UCB collaboration for KCNT1 program; up to ~$100M in milestones plus royalties.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Praxis Precision Medicines, Inc. reported financial results for fourth quarter and full year 2022.

Period: fourth quarter and full year 2022
Result: reported results

Exact text from the filing

On February 7, 2023 , Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter and full year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Praxis Precision Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0001689548-23-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.